# Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma

> **NCT01557114** · PHASE1 · TERMINATED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 19 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Ipilimumab
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT01557114
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-03
- **Primary completion:** 2015-11
- **Final completion:** 2016-03
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** New compounds available in the indication (nivolumab/pembrolizumab), toxicity of ipilimumab
- **Last updated:** 2016-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01557114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01557114, "Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01557114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*